Search Result

Results for "

Colorectal cancer model

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acyltransferase (1) Akt (6) Anaplastic lymphoma kinase (ALK) (1) Apoptosis (8) Atg7 (1) Autophagy (5) Bacterial (1) c-Met/HGFR (2) Caspase (2) CDK (1) Cytochrome P450 (1) DNA/RNA Synthesis (1) EGFR (2) Epigenetic Reader Domain (1) ERK (2) FLT3 (1) Fungal (1) Guanylate Cyclase (2) HDAC (1) Histone Demethylase (1) HIV (1) mAChR (3) MDM-2/p53 (1) MEK (1) Methionine Adenosyltransferase (MAT) (1) MMP (1) mTOR (1) p38 MAPK (3) p62 (1) PARP (1) PD-1/PD-L1 (1) PDK-1 (1) PERK (1) Phosphatase (1) Phosphodiesterase (PDE) (1) PI3K (1) Platelet-activating Factor Receptor (PAFR) (1) Porcupine (1) PROTACs (3) Raf (2) STAT (2) STING (1) Survivin (1) TAM Receptor (1) TGF-beta/Smad (1) TGF-β Receptor (1) Trk Receptor (1) TRP Channel (1) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (30) Cardiovascular Disease (1) Infection (3) Inflammation/Immunology (3) Metabolic Disease (3) Neurological Disease (4)

By Targets:

Acyltransferase (1)

Akt (6)

Anaplastic lymphoma kinase (ALK) (1)

Apoptosis (8)

Atg7 (1)

Autophagy (5)

Bacterial (1)

c-Met/HGFR (2)

Caspase (2)

CDK (1)

Cytochrome P450 (1)

DNA/RNA Synthesis (1)

EGFR (2)

Epigenetic Reader Domain (1)

ERK (2)

FLT3 (1)

Fungal (1)

Guanylate Cyclase (2)

HDAC (1)

Histone Demethylase (1)

HIV (1)

mAChR (3)

MDM-2/p53 (1)

MEK (1)

Methionine Adenosyltransferase (MAT) (1)

MMP (1)

mTOR (1)

p38 MAPK (3)

p62 (1)

PARP (1)

PD-1/PD-L1 (1)

PDK-1 (1)

PERK (1)

Phosphatase (1)

Phosphodiesterase (PDE) (1)

PI3K (1)

Platelet-activating Factor Receptor (PAFR) (1)

Porcupine (1)

PROTACs (3)

Raf (2)

STAT (2)

STING (1)

Survivin (1)

TAM Receptor (1)

TGF-beta/Smad (1)

TGF-β Receptor (1)

Trk Receptor (1)

TRP Channel (1)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (30)

Cardiovascular Disease (1)

Infection (3)

Inflammation/Immunology (3)

Metabolic Disease (3)

Neurological Disease (4)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: BCRP

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P3099

Uroguanylin (human)	Guanylate Cyclase	Cancer
Uroguanylin (human) is a natural ligand for the Guanylyl Cyclase (GCC) receptor expressed in metastatic colorectal cancer tumors. Uroguanylin (human) has anti-tumor actions in an animal model for human colon cancer .

HY-P3099A

Uroguanylin (human) TFA	Guanylate Cyclase	Cancer
Uroguanylin (human) (TFA) is a natural ligand for the Guanylyl Cyclase (GCC) receptor expressed in metastatic colorectal cancer tumors. Uroguanylin (human) (TFA) has anti-tumor actions in an animal model for human colon cancer .

HY-W998345

SMART1	PROTACs PDK-1 Akt	Cancer
SMART1 is a highly specific and CRBN-dependent PROTAC that can effectively degrade Smurf1. SMART1 can block the PDK1-Akt signaling pathway in KRAS mutant colorectal cancer. SMART1 can inhibit tumor growth in KRAS mutant colorectal cancer (CRC) xenograft models.(Blue: CRBN ligand; Black: linker; Pink: Smurf1 ligand (Smurf1-L)) .

HY-10834

β-catenin-IN-6	β-catenin	Cancer
β-catenin-IN-6 is a β-catenin inhibitor, targeting to canonical Wingless-related integration site signaling pathway. β-catenin-IN-6 inhibits human colorectal cancer cells proliferation, as well as in a β-catenin/RK3E mouse model .

HY-150636

Autophagy-IN-1	Autophagy Apoptosis	Cancer
Autophagy-IN-1 is a potent autophagy/mitophagy inhibitor, acts by selectively increasing the autophagic flux while blocking the autophagosome-lysosome fusion in cancer cells. Autophagy-IN-1 can induce apoptosis and cell cycle arrest. Autophagy-IN-1 significantly inhibits tumor growth in an HCT116 xenograft mouse model and with low toxicity. Autophagy-IN-1 can be used for researching colorectal cancer .

HY-15815

Bromosporine 3 Publications Verification	Epigenetic Reader Domain Apoptosis CDK HIV	Cancer
Bromosporine is a potent BET inhibitor with an IC₅₀ value of 2.1 μM for PCAF. Bromosporine can arrest cell cycle and induce apoptosis in cancer cells. Bromosporine exhibits excellent antitumor activity in xenograft mice model when combined with 5-FU (HY-90006). Bromosporine can increase CDK9 T-loop phosphorylation in HIV-1 latency models, resulting the protection of reactivate HIV-1 replication from latency. Bromosporine can be used to research colorectal cancer, acute myeloid leukemia (AML) and AIDS .

HY-169779

PTX80	p62	Cancer
PTX80 is an antagonist of p62 with an IC₅₀ value of 31.18 nM. PTX80 reduces tumor volume in an HCT116 colorectal cancer mouse xenograft model .

HY-164492

LSN3074753	Raf	Cancer
LSN3074753, an analog of LY3009120 (HY-12558), is a pan-RAF and Raf dimer inhibitor. LSN3074753 demonstrates activity against tumor cells with MAPK pathway activation driven by BRAF monomer or RAF dimers including BRAF- or KRAS-mutant colorectal cancer. LSN3074753 combined with Cetuximab (HY-P9905) shows additive and synergistic effects for colorectal cancer PDX models, particularly those with KRAS or BRAF mutation .

HY-170905S

MAT2A-IN-22	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-22 (Compound 29-1) is a BBB-penatrable and orally active MAT2A inhibitor with an IC₅₀ of 4 nM. MAT2A-IN-22 shows selectivity and inhibitory activity against MTAP-deficient cancer cell lines. MAT2A-IN-22 has anti-tumor effects .

HY-168933

KWR095	DNA/RNA Synthesis	Cancer
KWR095 is an orally active WRN inhibitor with an IC₅₀ of 0.032 μM for WRN ATPase. KWR095 can impede the duplex unwinding activity of WRN and inhibit the proliferation of tumor cells. KWR095 has anti-tumor activity .

HY-143905

PROTAC TTK degrader-2	PROTACs	Cancer
PROTAC TTK degrader-2 is a potent TTK (threonine tyrosine kinase) PROTAC degrader, with DC₅₀ values of 3.1 and 12.4 nM in COLO-205 and HCT-116 cell, respectively. PROTAC TTK degrader-2 exhibits target degradation and anticancer efficacy in a xenograft mouse model of COLO-205 human colorectal cancer cells .

HY-143904

PROTAC TTK degrader-1	PROTACs	Cancer
PROTAC TTK degrader-1 is a potent TTK (threonine tyrosine kinase) PROTAC degrader, with DC₅₀ values of 1.7 and 5.8 nM in COLO-205 and HCT-116 cell, respectively. PROTAC TTK degrader-1 exhibits target degradation and anticancer efficacy in a xenograft mouse model of COLO-205 human colorectal cancer cells .

HY-170594

Antitumor agent-192	Atg7 Autophagy	Cancer
Antitumor agent-192 (Compound 2f) is a β-carboline antitumor agent. Antitumor agent-192 induces autophagy in HCT116 cells via the ATG5/ATG7 pathway. Antitumor agent-192 has an IC₅₀ of less than 5 μM for human tumor cell lines and significantly inhibits tumor development and reduces tumor weight in a mouse colorectal cancer model transplanted with allografts ^[1].

HY-123237

KRC-108	c-Met/HGFR FLT3 Trk Receptor Apoptosis Autophagy	Cancer
KRC-108, an aminopyridine, is an orally active multiple kinase inhibitor with IC₅₀s of 80 nM, 23 nM, 3 nM, 70 nM, 30 nM, 39 nM for c-Met, c-Met M1250T, c-Met Y1230D, Ron, Flt3 and TrkA, respectively. KRC-108 induces cell cycle arrest, apoptotic cell death, and autophagy. KRC-108 exhibits anti-tumor activity in vivo in HT29 colorectal cancer, NCI-H441 lung cancer xenograft models in athymic BALB/c nu/nu mice .

HY-N8146

Bruceantinol	STAT	Infection Cancer
Bruceantinol, a quassinoid isolated from Brucea javanica, inhibits pepper mottle virus in pepper . Bruceantinol is a STAT3 inhibitor demonstrating potent antitumor activity in in vitro and in vivo human colorectal cancer (CRC) models. Bruceantinol strongly inhibits STAT3 DNA-binding ability (IC₅₀=2.4 pM), blocks the constitutive and IL-6-induced STAT3 activation, and suppresses transcription of MCL-1, PTTG1, survivin and c-Myc .

HY-173149

CDD-2789	Anaplastic lymphoma kinase (ALK) TGF-beta/Smad TGF-β Receptor	Cancer
CDD-2789 is a highly selective small-molecule inhibitor targeting Activin receptor type 1 (ALK2, also known as ACVR1). It blocks the SMAD1/5 signaling pathway mediated by ALK2/ALK1, thereby effectively suppressing downstream phosphorylation events induced by BMP and activin A. In the NanoBRET cellular model, CDD-2789 exhibits an inhibitory IC₅₀ of 0.54 µM against ALK2. CDD-2789 holds promise for research on ALK2-related diseases, including diffuse intrinsic pontine glioma (DIPG), ependymoma, endometrial cancer, melanoma, non–small cell lung cancer, colorectal cancer, and pancreatic cancer .

HY-163828

PPA24	Apoptosis Phosphatase	Cancer
PPA24 (commound 19a) is a PP2A activator. PPA24 can induce apoptosis and oxidative stress and reduce c-Myc expression levels. PPA24 can be used in anti-cancer research .

HY-162460

ERK1/2 inhibitor 10	ERK	Cancer
ERK1/2 inhibitor 10 (Compound 36c) is a potent ERK1 and ERK2 inhibitor (IC₅₀: 0.11 and 0.08 nM respectively). ERK1/2 inhibitor 10 inhibits ERK1/2 and blocks the phosphorylation expression of their downstream substrates p90RSK and c-Myc. ERK1/2 inhibitor 10 induces cell apoptosis and incomplete autophagy-related cell death. ERK1/2 inhibitor 10 shows potent antitumor efficacy against triple-negative breast cancer and colorectal cancer models harboring BRAF and RAS mutations .

HY-170954

C-Met/Axl-IN-1	Apoptosis c-Met/HGFR TAM Receptor	Cancer
C-Met/Axl-IN-1 (Compound 22a) is an orally active and selective type II c-Met/Axl inhibitor with IC₅₀ values of 1 nM and 10 nM, respectively. C-Met/Axl-IN-1 can inhibit proliferation, induce cell cycle arrest and apoptosis of tumor cells. C-Met/Axl-IN-1 has strong anti-tumor activity .

HY-P10914

D-CopA3	MDM-2/p53 Autophagy	Inflammation/Immunology Cancer
D-CopA3 is the inhibitor for MDM2 and the activator for p53 signaling pathway. D-CopA3 exhibits cytotoxicity in colorectal cancer cells HCT-116, LoVo, and RKO (IC₅₀=15-18 μM), induces JNK/Beclin-1 mediated autophagy. D-CopA3 downregulates the expression of cell cycle inhibitory protein p21Cip1/Waf1, enhances the mucosal barrier function and reduces penetration of inflammatory mediators. D-CopA3 exhibits anti-inflammtory activity in mouse C. difficile toxin A-induced acute enteritis models and DSS (HY-116282)-induced chronic colitis models. D-CopA3 exhibits antitumor efficacy in mouse HCT-116 xenograft models .

HY-162873

MEK/RAF-IN-1	MEK Raf	Cancer
MEK/RAF-IN-1 (Compound 16b) is an inhibitor of both MEK and RAF. It shows potent inhibition with IC₅₀ values of 28 nM for MEK1, and 3 nM each for BRAF and BRAFV600E. MEK/RAF-IN-1 demonstrates significant antitumor activity, effectively inhibiting cell proliferation in vitro against MIA PaCa-2 (G12C KRAS), HCT116 (G13D KRAS), and C26 (G12D KRAS) cells. Additionally, it inhibits tumor growth in xenograft mouse models of colorectal cancer .

HY-N0447

8-Gingerol 4 Publications Verification	TRP Channel Bacterial Apoptosis Autophagy STAT PERK EGFR PI3K Akt mTOR Caspase MMP	Infection Cardiovascular Disease Inflammation/Immunology Cancer
8-Gingerol can be found in the rhizome of ginger (Z. officinale) and has oral bioactivity. It activates TRPV1, with an EC₅₀ value of 5.0 µM. 8-Gingerol inhibits COX-2 and also suppresses the growth of H. pylori in vitro. Additionally, 8-Gingerol exhibits anticancer, antioxidant, and anti-inflammatory properties by inhibiting the epidermal growth factor receptor (EGFR) and modulating its downstream STAT3/ERK pathway to suppress the proliferation, migration, and invasion of colorectal cancer cells. 8-Gingerol also exerts immunosuppressive effects by inhibiting oxidative stress, inducing cell cycle arrest, promoting apoptosis, and regulating autophagy. Furthermore, 8-Gingerol has cardioprotective effects. 8-Gingerol is promising for research in the fields of cancer, infection, immunosuppression, and cardiovascular diseases.

HY-169938

LSD1/HDAC-IN-2	HDAC Histone Demethylase Apoptosis	Cancer
LSD1/HDAC-IN-2 (Compound 20c) is the inhibitor for LSD and HDAC, that inhibits LSD1, HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8, with IC₅₀s of 39.0, 1.4, 1.0, 1.3, 2.9 and 16.0 nM, respectively. LSD1/HDAC-IN-2 inhibits the proliferation of cancer cells, especially the colorectal cancer cells. LSD1/HDAC-IN-2 arrests the cell cycle at G2/M phase, inhibits cell migration, and induces apoptosis in HCT-116 and HT-29 cells. LSD1/HDAC-IN-2 exhibits antitumor efficacy in mouse model without significant toxicity .

HY-168491

Enpp-1-IN-25	Phosphodiesterase (PDE) STING PD-1/PD-L1	Cancer
Enpp-1-IN-25 (Compound 30) is an ENPP1 inhibitor with an IC₅₀ of 8.05 nM and low oral bioavailability. Enpp-1-IN-25 can effectively activate the intracellular STING pathway by inhibiting cGAMP degradation. Enpp-1-IN-25 can enhance immune cell infiltration in the tumor microenvironment and type I interferon responses, and potentiate the antitumor efficacy of the anti-PD-L1 antibody. Enpp-1-IN-25 can be used in the research of cancer immunotherapy .

HY-153855

Zamaporvint RXC004	Wnt Acyltransferase Porcupine	Cancer
Zamaporvint (RXC004) is an orally active and selective inhibitor of Wnt. Zamaporvint targete membrane-bound o-acyltransferase Porcupine and inhibited Wnt ligand palmitoylation, secretion, and pathway activation. Zamaporvint displays a favorable pharmacokinetic profile and shows potent antiproliferative effects in Wnt ligand-dependent colorectal and pancreatic cell lines. Zamaporvint possesses multiple antitumor mechanisms and can be used in cancer research .

HY-P99275

Patritumab 1 Publications Verification Human Anti-ERBB3 Recombinant Antibody	EGFR Akt ERK PARP Survivin	Cancer
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .

HY-N2071

Cedrol 1 Publications Verification (+)-Cedrol; α-Cedrol	Cytochrome P450 Fungal Apoptosis Caspase Platelet-activating Factor Receptor (PAFR)	Infection Neurological Disease Inflammation/Immunology Cancer
Cedrol is a potent competitive inhibitor of cytochrome P-450(CYP) enzyme. Cedrol plays an anticancer role by inducing cell cycle arrest and Caspase-dependent apoptosis. Cedrol acts as a neutrophil agonist that can desensitize cells to subsequent stimulation of N-formyl peptides. Cedrol prevents neuropathic pain caused by chronic contractile injury by inhibiting oxidative stress and inflammation. In addition, Cedrol has antibacterial, hair loss prevention and anti-anxiety properties .

HY-A0012

Darifenacin hydrobromide Maximum Cited Publications 6 Publications Verification UK-88525 hydrobromide	mAChR p38 MAPK Akt	Neurological Disease Metabolic Disease Cancer
Darifenacin (UK-88525) hydrobromide is a selective and orally active M3 muscarinic receptor (M3R) antagonist with a pKi of 8.9. Darifenacin hydrobromide binds >20-fold more specifically to M3R than to other muscarinic receptors. Darifenacin hydrobromide can be used in the study of urinary incontinence and other symptoms of overactive bladder. Darifenacin hydrobromide inhibits tumor growth in colorectal cancer cells and has anti-tumor effects .

HY-A0033

Darifenacin Maximum Cited Publications 6 Publications Verification UK-88525	mAChR p38 MAPK Akt	Neurological Disease Metabolic Disease Cancer
Darifenacin (UK-88525) is a selective and orally active M3 muscarinic receptor (M3R) antagonist with a pKi of 8.9. Darifenacin binds >20-fold more specifically to M3R than to other muscarinic receptors. Darifenacin can be used in the study of urinary incontinence and other symptoms of overactive bladder. Darifenacin inhibits tumor growth in colorectal cancer cells and has anti-tumor effects .

HY-A0012R

Darifenacin (hydrobromide) (Standard) UK-88525 (hydrobromide) (Standard)	mAChR p38 MAPK Akt	Neurological Disease Metabolic Disease Cancer
Darifenacin (hydrobromide) (Standard) is the analytical standard of Darifenacin (hydrobromide). This product is intended for research and analytical applications. Darifenacin (hydrobromide) is a selective and orally active M3 muscarinic receptor (M3R) antagonist with a pKi of 8.9. Darifenacin (hydrobromide) binds >20-fold more specifically to M3R than to other muscarinic receptors. Darifenacin (hydrobromide) can be used in the study of urinary incontinence and other symptoms of overactive bladder. Darifenacin (hydrobromide) inhibits tumor growth in colorectal cancer cells and has anti-tumor effects .

Cat. No.	Product Name	Target	Research Area